** Shares of Hansoh Pharmaceutical Group 3692.HK rise 3.8% to HK$27.5, their highest levels since August 2021
** Stock marks biggest intraday pct gain since May 20, and on track for a third straight session of rise, if current trend holds
** Stock is fifth-biggest pct gainer on the Hang Seng Commerce & Industry Index .HSNC, which climbs 0.8%
** Hansoh says its innovative drug Aumolertinib Mesilate Tablets for lung cancer has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for marketing
** The Hang Seng Biotech Index .HSHKBIO rises 3.1% and the Hang Seng Index .HSI adds 0.5%
** YTD, stock up 56.8%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。